Immuneering prices 6.3M shares at $3.95 in private placement

Immuneering (IMRX) entered into a definitive securities purchase agreement for a private placement of securities to top-tier institutional and other accredited investors, that is expected to result in up front gross proceeds to the Company of approximately $25M, before deducting fees and expenses. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about August 26, 2025. Under the securities purchase agreement, the investors agreed to purchase: an aggregate of 6,329,113 unregistered shares of the company’s Class A common stock at a purchase price of $3.95 per share, and accompanying purchase warrants to purchase an aggregate of 2,848,096 shares of Class A common stock, with each such warrant representing the right to purchase one share of the company’s Class A common stock at an exercise price of $5.50 per share. The pre-funded warrants were issued for a purchase price equating to $3.949 per pre-funded warrant share. The $3.95 per share purchase price for the Company’s Class A common stock represents a premium of approximately 15% as compared to the Company’s last reported closing price on August 20, 2025. The investors will be granted registration rights as part of the transaction. The purchase warrants will be exercisable for a period of five years following the date on which the Class A common stock issued and issuable in the transaction are registered for resale.